Longboard pharmaceuticals announces pricing of initial public offering

San diego, march 11, 2021 (globe newswire) -- longboard pharmaceuticals, inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. the gross proceeds to longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80.0 million.
LBPH Ratings Summary
LBPH Quant Ranking